Determination of NF-κB and RANKL levels in peripheral blood osteoclast precursor cells in chronic kidney disease patients
- 145 Downloads
Chronic kidney disease (CKD) is a progressive condition characterized by irreversible loss of functional nephron mass due to variety of causes; an inevitable complication of CKD is metabolic bone disease, and this pathology is called as renal osteodystrophy (ROD). In this study, we aimed to determine the levels of serum sRANKL and intracellular NF-κB levels in peripheral blood osteoclast precursor cells in patients with stage 3 CKD.
Materials and methods
Forty-one male patients aged 35–60 with CKD identified as stage 3 according to GFR calculated on the basis of creatinine values and 27 healthy male subjects with age ranging from 40 to 60 as control group were included in this study. Levels of biochemical parameters, vitamin D3, parathyroid hormone, bone mineral density, sRANKL and NF-κB were determined by using photometric, electrochemiluminescence, HPLC, ELISA and flow cytometric methods in control and patient groups, respectively.
When stage 3 CKD patients were compared with controls, patients with stage 3 CKD had statistically significantly higher iPTH levels, but they had statistically significantly lower vitamin D3 levels. However, the other biochemical parameters, bone mineral density, sRANKL and NF-κB levels did not reveal any significance.
In conclusion, vitamin D3 and iPTH levels seem to be important parameters for evaluating the early stages of ROD. The lack of statistically significant differences in the levels of sRANKL and NF-κB suggests that these parameters are not sufficient in the evaluation of bone metabolism in the early stages of renal failure.
KeywordsChronic kidney disease NF-κB Renal osteodystrophy sRANKL
This study was supported by the Scientific Research Projects Unit, Mersin University [BAP-TF (GG) 2009-8 TU].
Compliance with ethical standards
Conflict of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
- 1.D’Onofrio G, Simeoni M, Rizza P, Caroleo M, Capria M, Mazzitello G, Sacco T, Mazzuca E, Panzino MT, Cerantonio A, Segura-Garcia C, Andreucci M, De Fazio P, Fuiano G (2017) Quality of life, clinical outcome, personality and coping in chronic hemodialysis patients. Ren Fail 39(1):45–53. https://doi.org/10.1080/0886022X.2016.1244077 CrossRefPubMedGoogle Scholar
- 2.Bargman M, Skorecki K (2008) Chronic Kidney Disease. In: Fauci S, Kasper L, Braunwald E, Hauser K, Longo B, Jameson F (eds) Harrison’s principles of internal medicine, 17th edn. Mv Graw Hill, New York, pp 1761–1771Google Scholar
- 8.Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T (1999) Commitment and differentiation of osteoclast precursor cells by the sequential expression of C-Fms and receptor activator of nuclear factor κb (Rank) receptors. J Exp Med 190(12):1741–1754CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Pivetta E, Wassermann B, Bulian P, Steffan A, Colombatti A, Polesel J, Spessotto P (2015) Functional osteoclastogenesis: the baseline variability in blood donor precursors is not associated with age and gender. Oncotarget 6(31):31889–31900. https://doi.org/10.18632/oncotarget.5575 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.EPI CKD Calculator. http://www.MDRD.com/. Accessed 26 June 2010
- 23.Shin SK, Kim DH, Kim HS, Shin KT, Ma KA, Kim SJ, Kwak YS, Ha SK, Sherrard DJ (1999) Renal osteodystrophy in pre-dialysis patients: ethnic difference? Perit Dial Int 19(Suppl 2):402–407Google Scholar
- 25.Martínez-Castelao A, Górriz JL, Portolés JM, De Alvaro F, Cases A, Luño J, Navarro-González JF, Montes R, De la Cruz-Troca JJ, Natarajan A, Batlle D (2011) Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational cohort study. BMC Nephrol 5(12):53. https://doi.org/10.1186/1471-2369-12-53 CrossRefGoogle Scholar
- 28.Kurajoh M, Inaba M, Yamada S, Imanishi Y, Tsuchida T, Ishimura E, Nishizawa Y (2008) Association of increased active PTH(1–84) fraction with decreased GFR and serum Ca in predialysis CR patients: modulation by serum 25-OH-D. Osteoporos Int 19(5):709–716. https://doi.org/10.1007/s00198-007-0554-2 CrossRefPubMedGoogle Scholar
- 31.Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A (2009) Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease. Ther Apher Dial 13(1):49–55. https://doi.org/10.1111/j.1744-9987.2009.00653.x CrossRefPubMedGoogle Scholar
- 32.Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, Tziamalis MP, Tsigris C, Kostaki MA, Perrea DN (2007) sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients. J Endocrinol Invest 30(9):762–766. https://doi.org/10.1007/BF03350814 CrossRefPubMedGoogle Scholar